CBO score doesn’t settle contest over H.R. 3

A Congressional Budget Office estimate of savings and impacts of the Lower Drug Costs Now Act of 2019 (H.R. 3) provides ammunition to both House Democrats who support the bill and to Senate Republicans who are certain to reject it.

The bill, which seeks to create a ceiling for Medicare Part D drug prices based on an index of prices in six countries, would “reduce federal direct spending for Medicare by $345 billion over the 2023-2029 period,” CBO said...